GDOC Quote, Financials, Valuation and Earnings

Fidelity Disruptive Medicine ETF has a net margin of -- compared to Goldman Sachs Future Health Care Equity ETF's net margin of --. Goldman Sachs Future Health Care Equity ETF's return on equity of -- beat Fidelity Disruptive Medicine ETF's return on equity of --.

Goldman Sachs Future Health Care Equity ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity Disruptive Medicine ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Goldman Sachs Future Health Care Equity ETF has higher upside potential than Fidelity Disruptive Medicine ETF, analysts believe Goldman Sachs Future Health Care Equity ETF is more attractive than Fidelity Disruptive Medicine ETF.

Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fidelity Disruptive Medicine ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Goldman Sachs Future Health Care Equity ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.02%. Fidelity Disruptive Medicine ETF offers a yield of 0.45% to investors and pays a quarterly dividend of $0.11 per share. Goldman Sachs Future Health Care Equity ETF pays -- of its earnings as a dividend. Fidelity Disruptive Medicine ETF pays out -- of its earnings as a dividend.

Goldman Sachs Future Health Care Equity ETF quarterly revenues are --, which are smaller than Fidelity Disruptive Medicine ETF quarterly revenues of --. Goldman Sachs Future Health Care Equity ETF's net income of -- is lower than Fidelity Disruptive Medicine ETF's net income of --. Notably, Goldman Sachs Future Health Care Equity ETF's price-to-earnings ratio is -- while Fidelity Disruptive Medicine ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldman Sachs Future Health Care Equity ETF is -- versus -- for Fidelity Disruptive Medicine ETF. Usually stocks with elevated PS ratios are considered overvalued.

Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to Goldman Sachs Future Health Care Equity ETF's net margin of --. Goldman Sachs Future Health Care Equity ETF's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.

Goldman Sachs Future Health Care Equity ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Goldman Sachs Future Health Care Equity ETF has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe Goldman Sachs Future Health Care Equity ETF is more attractive than Invesco Nasdaq Biotechnology ETF.

Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Goldman Sachs Future Health Care Equity ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.02%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.12% to investors and pays a quarterly dividend of $0.06 per share. Goldman Sachs Future Health Care Equity ETF pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.

Goldman Sachs Future Health Care Equity ETF quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. Goldman Sachs Future Health Care Equity ETF's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, Goldman Sachs Future Health Care Equity ETF's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldman Sachs Future Health Care Equity ETF is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.

Harbor Health Care ETF has a net margin of -- compared to Goldman Sachs Future Health Care Equity ETF's net margin of --. Goldman Sachs Future Health Care Equity ETF's return on equity of -- beat Harbor Health Care ETF's return on equity of --.

Goldman Sachs Future Health Care Equity ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Harbor Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Goldman Sachs Future Health Care Equity ETF has higher upside potential than Harbor Health Care ETF, analysts believe Goldman Sachs Future Health Care Equity ETF is more attractive than Harbor Health Care ETF.

Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harbor Health Care ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Goldman Sachs Future Health Care Equity ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.02%. Harbor Health Care ETF offers a yield of 0.53% to investors and pays a quarterly dividend of $0.13 per share. Goldman Sachs Future Health Care Equity ETF pays -- of its earnings as a dividend. Harbor Health Care ETF pays out -- of its earnings as a dividend.

Goldman Sachs Future Health Care Equity ETF quarterly revenues are --, which are smaller than Harbor Health Care ETF quarterly revenues of --. Goldman Sachs Future Health Care Equity ETF's net income of -- is lower than Harbor Health Care ETF's net income of --. Notably, Goldman Sachs Future Health Care Equity ETF's price-to-earnings ratio is -- while Harbor Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldman Sachs Future Health Care Equity ETF is -- versus -- for Harbor Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.

Roundhill GLP-1 & Weight Loss ETF has a net margin of -- compared to Goldman Sachs Future Health Care Equity ETF's net margin of --. Goldman Sachs Future Health Care Equity ETF's return on equity of -- beat Roundhill GLP-1 & Weight Loss ETF's return on equity of --.

Goldman Sachs Future Health Care Equity ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Roundhill GLP-1 & Weight Loss ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Goldman Sachs Future Health Care Equity ETF has higher upside potential than Roundhill GLP-1 & Weight Loss ETF, analysts believe Goldman Sachs Future Health Care Equity ETF is more attractive than Roundhill GLP-1 & Weight Loss ETF.

Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Goldman Sachs Future Health Care Equity ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.02%. Roundhill GLP-1 & Weight Loss ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Goldman Sachs Future Health Care Equity ETF pays -- of its earnings as a dividend. Roundhill GLP-1 & Weight Loss ETF pays out -- of its earnings as a dividend.

Goldman Sachs Future Health Care Equity ETF quarterly revenues are --, which are smaller than Roundhill GLP-1 & Weight Loss ETF quarterly revenues of --. Goldman Sachs Future Health Care Equity ETF's net income of -- is lower than Roundhill GLP-1 & Weight Loss ETF's net income of --. Notably, Goldman Sachs Future Health Care Equity ETF's price-to-earnings ratio is -- while Roundhill GLP-1 & Weight Loss ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldman Sachs Future Health Care Equity ETF is -- versus -- for Roundhill GLP-1 & Weight Loss ETF. Usually stocks with elevated PS ratios are considered overvalued.